Meander Medisch Centrum Stichting

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Metastatic breast cancer2 trials
• Prostate cancer2 trials
• Asthma1 trial
• Childhood cancers1 trial
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Diffuse large B-cell lymphoma1 trial
• Hodgkin lymphoma1 trial
• Multiple myeloma1 trial
• Stroke1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 38 trials
• Phase 23 trials
• Phase 1/21 trial

Status

• Recruiting6 trials
• Active, not recruiting4 trials
• Completed2 trials

Lead sponsor

• Merck Sharp & Dohme LLC4 trials
• Amgen2 trials
• AstraZeneca2 trials
• Blue Earth Therapeutics Ltd1 trial
• Genmab1 trial
• and 2 more

Running trials

• Recruiting

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  NCT06312137· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

• Active, not recruiting

  Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

  NCT06087835· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT05578976· Phase 3· Genmab· Source

• Recruiting

  Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

  NCT05413850· Phase 1/2· Blue Earth Therapeutics Ltd· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

  NCT04895358· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  DRUP trial

  NCT02925234· Phase 2· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Source

• Active, not recruiting

  Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

  NCT01898117· Phase 2· The Netherlands Cancer Institute· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Prostate cancer2 recruiting
• Hodgkin lymphoma1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· AstraZeneca· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source